Arca
Skip to content
Tools
Tools

IFNAR1, IFNAR2: Interferon alpha/beta receptor

Complex in Homo sapiens that 11 drugs act on.

  • Drugs that act on it: 11
  • Approved: 10
  • In phases 1 to 3: 1
  • Sponsors: 9

Who is on it, and how far along

Every drug ChEMBL records acting on IFNAR1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Protein or peptide 10
  • Other 1

Approved10

  • Interferon alfa-2b
  • Peginterferon alfa-2b
  • Ropeginterferon alfa-2b
  • Interferon beta-1a
  • Peginterferon alfa-2a
  • Interferon alfa-2a
  • Peginterferon beta-1a
  • Interferon beta-1b
  • Interferon alfa-N3
  • Interferon alfaCON-1

Phase 31

Phase 20

    Phase 10

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 10 of 11 act as: Interferon alpha/beta receptor agonist; the rest name their own mechanism.
      Interferon alfa-2bBoxed warningApprovedMerck & Co. (MSD)Protein or peptideAgonist31
      Peginterferon alfa-2bBoxed warningApprovedMerck & Co. (MSD)Protein or peptideAgonist21
      Ropeginterferon alfa-2bApprovedPharmaEssentiaProtein or peptidePositive modulatorInterferon alpha/beta receptor positive modulator20
      Interferon beta-1aApprovedBiogenProtein or peptideAgonist8
      Peginterferon alfa-2aBoxed warningApprovedPharmaandProtein or peptideAgonist8
      Interferon alfa-2aBoxed warningApprovedIncyteProtein or peptideAgonist5
      Peginterferon beta-1aApprovedBiogenProtein or peptideAgonist4
      Interferon beta-1bApprovedBayerProtein or peptideAgonist2
      Interferon alfa-N3ApprovedInterferon SciencesProtein or peptideAgonist0
      Interferon alfaCON-1Boxed warningApprovedAstellas PharmaProtein or peptideAgonist0
      Albinterferon alfa-2bPhase 3GSKOtherAgonist0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 33 in all, from ClinicalTrials.gov.
      Interferon-α Maintenance in Favorable-Risk AMLInterferon alfa-2b, Peginterferon alfa-2bPhase 2RecruitingPeking University People's HospitalNov 9, 2026
      Peg IFNα-2b Therapy for Unresectable Mid to Late Stage HBV-HCCInterferon alfa-2b, Peginterferon alfa-2bNot applicableRecruitingJinling Hospital, ChinaAug 18, 2026
      Standardized Documentation and Assessments for Polycythemia Vera: A Quality Improvement InitiativeRopeginterferon alfa-2bNot applicableRecruitingMassachusetts General HospitalJul 29, 2026
      A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025).Ropeginterferon alfa-2bPhase 2 / Phase 3RecruitingMerck Sharp & Dohme LLCJul 23, 2026
      A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in MDS/AML With TP53 MutationsRopeginterferon alfa-2bPhase 1 / Phase 2RecruitingM.D. Anderson Cancer CenterJun 15, 2026
      Thermosensitive Gel Nasal Spray With Exosomes, Azelastine, and Interferon for Acute Phase of Chronic SinusitisInterferon alfa-2bEarly phase 1Not yet recruitingThe First Affiliated Hospital of Xinxiang Medical CollegeJun 9, 2026
      Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian CancerInterferon alfa-2aPhase 2Not yet recruitingKalinski, Pawel, MD, PhDJun 8, 2026
      A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential ThrombocythemiaInterferon alfa-2b, Peginterferon alfa-2a, Peginterferon alfa-2b, Ropeginterferon alfa-2b, Interferon alfa-2aPhase 3RecruitingIncyte CorporationJun 3, 2026
      Risk Factors for Tooth Eruption DiseasesInterferon alfa-2bNot applicableNot yet recruitingFondazione Policlinico Universitario Agostino Gemelli IRCCSMay 14, 2026
      Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical ResectionInterferon alfa-2b, Peginterferon alfa-2bEarly phase 1Not yet recruitingNingbo No.2 HospitalApr 28, 2026
      Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in MyelofibrosisRopeginterferon alfa-2bPhase 1RecruitingUniversity of UtahApr 9, 2026
      Effect of Storytelling on Questionnaire Completion and Quality of Collected Data in an E-CohortPeginterferon alfa-2aNot applicableNot yet recruitingSKEZIMar 16, 2026
      Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic LeukemiaInterferon alfa-2b, Peginterferon alfa-2b, Ropeginterferon alfa-2bPhase 2Not yet recruitingJonsson Comprehensive Cancer CenterMar 13, 2026
      A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PVInterferon alfa-2b, Peginterferon alfa-2bNot applicableRecruitingDuan MinghuiMar 3, 2026
      Safety, Tolerability, and Preliminary Efficacy of Peginterferon α-2b in Combination With an Anti-PD-1 Antibody in Patients With Advanced or Metastatic Malignant Solid TumorsPeginterferon alfa-2bNot applicableNot yet recruitingThe First Affiliated Hospital of Xiamen UniversityFeb 27, 2026
      A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis BPeginterferon alfa-2aPhase 1RecruitingIntegerBioFeb 5, 2026
      DOC1021 Dendritic Cell Immunotherapy for Refractory MelanomaPeginterferon alfa-2aPhase 1 / Phase 2RecruitingDiakonos Oncology CorporationDec 17, 2025
      Evaluation of Real-World Data on Ropeginterferon Alfa-2b in Patients With Polycythemia Vera: Insights From a Multicenter StudyRopeginterferon alfa-2b—Not yet recruitingFederico II UniversityDec 15, 2025
      Phase I/II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic PhaseRopeginterferon alfa-2bPhase 1 / Phase 2RecruitingM.D. Anderson Cancer CenterDec 8, 2025
      Prospective Cohort Study on PEG-IFN-α-2b in Improving Clinical Cure Rate of Pediatric Patients With Chronic Hepatitis BPeginterferon alfa-2bPhase 4Not yet recruitingNanfang Hospital, Southern Medical UniversityNov 17, 2025
      VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis BPeginterferon alfa-2aPhase 2Active, not recruitingNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Oct 23, 2023
      A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)Peginterferon alfa-2a, Interferon alfa-2aPhase 3Active, not recruitingMerck Sharp & Dohme LLCOct 12, 2023
      Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.Peginterferon alfa-2aPhase 3RecruitingBriaCell Therapeutics CorporationOct 10, 2023
      An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and SwedenInterferon beta-1a, Interferon beta-1b, Peginterferon beta-1a—Active, not recruitingBayerSep 26, 2023
      Nivolumab in Children and Adults With Nasopharyngeal CarcinomaInterferon beta-1aPhase 2RecruitingGerman Society for Pediatric Oncology and Hematology GPOH gGmbHAug 31, 2023
      A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their BabiesInterferon beta-1a, Peginterferon beta-1a—Active, not recruitingBiogenJan 18, 2023
      Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)Interferon beta-1a—RecruitingBiogenDec 20, 2022
      AlloHCT With PegINFa for MyelofibrosisPeginterferon alfa-2a, Interferon alfa-2aPhase 1RecruitingUniversity of UtahSep 10, 2022
      MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia VeraInterferon alfa-2aPhase 3RecruitingUniversity of BirminghamOct 4, 2019
      A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple SclerosisInterferon beta-1a, Peginterferon beta-1aPhase 3Active, not recruitingBiogenMay 22, 2019
      Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMSInterferon beta-1a, Interferon beta-1b, Peginterferon beta-1aPhase 4Active, not recruitingThe Cleveland ClinicMay 24, 2018
      Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaInterferon beta-1aPhase 3RecruitingUMC UtrechtApr 13, 2016
      Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple SclerosisInterferon beta-1aPhase 3Active, not recruitingNovartis PharmaceuticalsJul 4, 2013

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2364170, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.